Pulmonary hypertension
We understand the ways in which pulmonary hypertension and pulmonary arterial hypertension can impair daily life. We are committed to helping to improve understanding of these diseases within the medical profession.
What is PH?
Pulmonary Hypertension (PH) is a progressive disease with various causes and no cure. PH is a wide term used to describe the presence of high blood pressure in the lung circulation due to any cause.
Of the five groups of PH, our research is focused on improving patient outcomes in Pulmonary Arterial Hypertension (PAH) as well as other groups.
PAH is caused by the walls of the arteries in the lungs becoming tighter and narrower. The pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart.
Of the five groups of PH, our research is focused on improving patient outcomes in Pulmonary Arterial Hypertension (PAH) as well as other groups.
PAH is caused by the walls of the arteries in the lungs becoming tighter and narrower. The pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart.
PAH is a rare disease
It is estimated that approximately 5,000 Canadians have been diagnosed with PH, but as many as 10,000 may be affected by the condition.1 PAH affects women, men, and children of any age or ethnic background.
Our research
Our research is focused on improving patient outcomes in PAH. Johnson & Johnson Innovative Medicine’s vision is to transform PAH into a long-term manageable condition and to one day find a cure for it.
Johnson & Johnson Innovative Medicine, we are committed to transforming pulmonary arterial hypertension into a long-term manageable condition so that patients can live their lives fully, now.”
Dr. Ebele Ola
VP Medical Affairs, Canada
1 PHA Canada link Accessed April 19, 2021